Neuropathic Pain Management: A Practical Guide to First-, Second-, and Third-Line Therapy

Clinical Practice Update — Drug Selection by Comorbidity, Combination Therapy, Topical Options, Trigeminal Neuralgia, and When to Refer

This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.

MDA-NP-2026·14 min read

Clinical Focus

Pharmacological management of neuropathic pain across aetiologies (diabetic neuropathy, postherpetic neuralgia, radiculopathy, central pain), first-line drug selection guided by comorbidities, combination therapy, topical options, trigeminal neuralgia, and opioid stewardship

Target Audience

Neurologists, primary care physicians, pain specialists, diabetologists, geriatricians, pharmacists

Setting

Primary care, neurology clinics, pain clinics, diabetic foot clinics

Source Evidence

•NeuPSIG 2015 — Pharmacotherapy for Neuropathic Pain: Systematic Review, Meta-Analysis and Updated Recommendations
•NICE CG173 (2013, updated 2025) — Neuropathic Pain: Pharmacological Management
•OPTION-DM Trial (Tesfaye et al., Lancet 2022) — Amitriptyline, Duloxetine, Pregabalin Monotherapy and Combinations for Painful Diabetic Neuropathy
•AAN 2011 — Treatment of Painful Diabetic Neuropathy
•French Society of Neurology 2020 / German Society of Neurology 2019 — National Neuropathic Pain Guidelines

Key Clinical Takeaways

Neuropathic pain management stepwise approach showing first-line drugs comorbidity-based selection and combination therapy options — Stepwise approach to neuropathic pain pharmacotherapy from first-line monotherapy through combination and specialist referral.

1First-line options are amitriptyline, duloxetine, gabapentin, or pregabalin — all have equivalent overall efficacy (OPTION-DM trial); choose based on comorbidities and side-effect profile → First-Line
2If monotherapy at maximum tolerated dose is insufficient, combination therapy from different drug classes (e.g., pregabalin + duloxetine) is more effective than dose escalation of a single agent → Combination Therapy
3Trigeminal neuralgia is an exception: carbamazepine (or oxcarbazepine) is the specific first-line treatment — the four standard neuropathic pain drugs are NOT effective for this condition → Trigeminal Neuralgia
4Avoid amitriptyline in elderly patients (>65 years) at doses above 75 mg/day due to anticholinergic burden, cardiac risk, and falls — duloxetine or gabapentin may be safer alternatives → Special Populations
5Pregabalin is a federally controlled substance in the USA (Schedule V) and UK (Class C). Gabapentin is Class C in the UK but is not a federally scheduled substance in the USA, though many individual states have added scheduling requirements — evaluate patients for substance use history before prescribing either drug → Drug Safety
6Topical lidocaine 5% patches and capsaicin 8% patches are second-line options for focal peripheral neuropathic pain — they have fewer systemic side effects and may be preferred in the elderly → Topical Therapy
7Do not start long-term opioids for neuropathic pain in non-specialist settings — strong opioids are third-line only, require specialist oversight, and carry risks of dependence, tolerance, and cognitive impairment → Opioids
8Always assess pain as part of a broader picture: sleep disturbance, mood, function, and quality of life should all be treatment targets → Holistic Assessment
9Duloxetine requires doses of at least 60 mg/day to be effective for neuropathic pain — doses below 60 mg are not effective for pain (though they may help depression) → Dosing
10NeuPSIG recommends against cannabinoids and valproate for neuropathic pain, and strongly recommends against levetiracetam and mexiletine → Drugs to Avoid

How Should You Choose a First-Line Drug?

The four first-line agents have similar overall efficacy but different side-effect profiles. The OPTION-DM trial confirmed that amitriptyline, duloxetine, and pregabalin are equally effective as monotherapy for painful diabetic neuropathy, and that combination therapy provides additional benefit when monotherapy fails. Choice should be individualised based on comorbidities, concurrent medications, and patient preference.

Neuropathic Pain Medications: Choosing by Patient Profile

Drug	Effective Dose Range	Favoured When	Avoid or Use Caution When	NeuPSIG NNT
Amitriptyline	25–75 mg at bedtime (max 150 mg)	Comorbid insomnia; low cost; younger patients without cardiac risk	Age >65 (anticholinergic); cardiac disease; glaucoma; urinary retention; orthostatic hypotension. Risk of sudden cardiac death at >100 mg/day	3.6
Duloxetine	60–120 mg daily (start 30 mg, increase after 1–2 weeks)	Comorbid depression/anxiety; diabetic neuropathy (FDA-approved); elderly patients	Significant liver disease; severe renal impairment (CrCl <30); concurrent MAOIs. Doses <60 mg/day not effective for pain	6.4
Pregabalin	150–600 mg daily in 2 divided doses	Comorbid anxiety (GAD); central neuropathic pain; rapid dose titration possible	Peripheral oedema; weight gain; history of substance abuse (controlled substance); renal impairment (dose-adjust)	7.7
Gabapentin	1200–3600 mg daily in 3 divided doses	Postherpetic neuralgia (FDA-approved); renal impairment (dose-adjustable); lower cost than pregabalin	Same cautions as pregabalin; slower titration needed; TID dosing may reduce adherence	6.3

NNT = number needed to treat for 50% pain relief. Lower NNT indicates greater efficacy. NNTs are from the NeuPSIG 2015 meta-analysis.
Allow adequate trial duration (4–8 weeks at maximum tolerated dose) before concluding treatment failure.
Venlafaxine (150–225 mg/day) is an alternative SNRI with neuropathic pain evidence, though less studied than duloxetine.

Clinical Pearl — OPTION-DM Trial: This landmark crossover RCT for painful diabetic neuropathy (Tesfaye et al., Lancet 2022) showed that amitriptyline, duloxetine, and pregabalin had equivalent efficacy as monotherapy. Critically, combination therapy (adding a drug from a different class) provided significantly greater pain relief than escalating monotherapy to maximum dose. This supports a “combine before you maximise” approach when first-line monotherapy at moderate doses is insufficient.

Clinical Decision Pathway

Neuropathic Pain: 4 Questions

Question 1: Is this neuropathic pain?

Features suggesting neuropathic pain: burning, shooting, electric shock-like quality; allodynia or hyperalgesia; distribution in a neuroanatomically plausible territory; associated sensory loss.

Use a screening tool (DN4 ≥4/10, or painDETECT ≥19) to support the clinical diagnosis.

Question 2: Is this trigeminal neuralgia?

Yes → Carbamazepine 200–1200 mg/day (or oxcarbazepine 600–1800 mg/day) is first-line. Do NOT use amitriptyline, duloxetine, pregabalin, or gabapentin. Refer early if medical treatment fails.

No → Proceed to standard neuropathic pain treatment algorithm.

Question 3: Which first-line drug fits this patient?

Insomnia predominant → Amitriptyline (sedating; give at bedtime).

Comorbid depression/anxiety → Duloxetine (or venlafaxine).

Elderly or cardiac risk → Duloxetine or gabapentin (avoid amitriptyline >75 mg).

Comorbid GAD → Pregabalin (also licensed for GAD).

Focal peripheral pain (e.g., postherpetic neuralgia) → Consider topical lidocaine 5% patch or capsaicin 8% patch as an alternative or adjunct.

Renal impairment → Dose-adjust gabapentin/pregabalin; avoid duloxetine if CrCl <30.

Question 4: Monotherapy failed — what next?

Step 1: Switch to another first-line agent from a different class (try all four before escalating).

Step 2: Combine two first-line agents from different classes (e.g., pregabalin + duloxetine, or gabapentin + amitriptyline).

Step 3: Consider second-line options (tramadol for short-term rescue, topical agents for focal pain).

Step 4: Refer to specialist pain service. Third-line options include strong opioids (with strict monitoring), botulinum toxin A (focal peripheral pain), or spinal cord stimulation.

Evidence in Context

Where NeuPSIG, NICE, and AAN Agree

All major guidelines agree on TCAs (amitriptyline), SNRIs (duloxetine), and gabapentinoids (pregabalin, gabapentin) as first-line agents. All recommend against long-term opioid use as initial therapy. NICE and NeuPSIG agree that carbamazepine is the specific first-line for trigeminal neuralgia. They differ modestly on the positioning of topical agents: NeuPSIG places lidocaine patches and capsaicin patches as second-line with a weak recommendation, while NICE permits capsaicin cream (not patches) in non-specialist settings and restricts capsaicin 8% patches to specialist initiation.

The Problem of Modest Efficacy and Large Placebo Responses

NNTs for first-line agents range from 3.6 (amitriptyline) to 7.7 (pregabalin), meaning that for every 4–8 patients treated, only one achieves 50% pain relief beyond placebo. Placebo response rates in neuropathic pain trials can reach 30–40%, particularly in diabetic neuropathy and HIV neuropathy. This modest drug efficacy underscores the importance of setting realistic expectations with patients, using validated outcome measures, addressing comorbid sleep and mood disorders, and incorporating non-pharmacological approaches (physiotherapy, CBT, TENS) alongside medication.

What We Still Don’t Know

Phenotype-guided treatment: Emerging evidence (e.g., from the COMBO-DN trial) suggests that specific pain phenotypes (burning vs evoked vs paraesthesia-dominant) may predict response to individual drugs. Clinical implementation of phenotypic profiling remains investigational.

Optimal combination regimens: The OPTION-DM trial showed benefit of combination therapy, but the optimal pairing and dose ratio for each patient remain undefined.

Role of cannabinoids: NeuPSIG 2015 recommended against cannabinoids for neuropathic pain. Subsequent trials have produced mixed results, and no major guideline has changed this position.

Long-term outcomes: Most RCTs last 8–12 weeks. Long-term efficacy, safety, and discontinuation strategies are poorly studied for all neuropathic pain drugs.

References

1.Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for Neuropathic Pain in Adults: A Systematic Review and Meta-Analysis (NeuPSIG). Lancet Neurol. 2015;14(2):162–173. doi:10.1016/S1474-4422(14)70251-0
2.National Institute for Health and Care Excellence. Neuropathic Pain in Adults: Pharmacological Management in Non-Specialist Settings. NICE Clinical Guideline CG173. Published November 2013, last updated March 2025. nice.org.uk/guidance/cg173
3.Tesfaye S, Sloan G, Petrie J, et al. Comparison of Amitriptyline Supplemented With Pregabalin, Pregabalin Supplemented With Amitriptyline, and Duloxetine Supplemented With Pregabalin for the Treatment of Diabetic Peripheral Neuropathic Pain (OPTION-DM): A Multicentre, Double-Blind, Randomised Crossover Trial. Lancet. 2022;400(10353):680–690. doi:10.1016/S0140-6736(22)01472-6
4.Bril V, England J, Franklin GM, et al. Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy. Neurology. 2011;76(20):1758–1765. doi:10.1212/WNL.0b013e3182166ebe
5.Schlereth T. Guideline: Diagnosis and Non-Interventional Therapy of Neuropathic Pain of the German Society of Neurology (DGN). Neurol Res Pract. 2020;2:16. doi:10.1186/s42466-020-00063-3

How to Read the Evidence Tags

Every recommendation carries two tags. These are Medaptly’s own simplified interpretations.

Recommendation Strength

Tag	Meaning	In Practice
Strong Rec	Benefits clearly outweigh risks.	Standard practice.
Moderate Rec	Evidence favours benefit; some uncertainty.	Most patients should receive this.
Conditional Rec	Benefit less certain; individualise.	Shared decision-making.
Against	No benefit or risks outweigh benefits.	Avoid.

Evidence Quality

Tag	Meaning	Confidence
High Evidence	Multiple RCTs or meta-analyses.	Very confident.
Moderate Evidence	Single RCT or large observational studies.	Reasonably confident.
Low Evidence	Expert consensus or small studies.	Less certain.

These are Medaptly’s simplified interpretations. For full classification systems, consult the original documents in References.

Article Information

For Educational Purposes Only. This is original clinical education content informed by current published guidelines and clinical evidence. It does not constitute medical advice, is not endorsed by any guideline body (IASP, NeuPSIG, NICE, AAN, or any other organisation), and does not replace individualised clinical judgement, institutional protocols, or local formulary guidance. Drug dosages should always be verified against current prescribing information. Readers are encouraged to consult the original source guidelines listed in the References section for the full evidence review and complete recommendation sets.